M a n u s c r i p t 2 HIV-associated cryptococcal meningitis continues to pose a major clinical challenge. Mortality rates of 20-40% have been reported in recent clinical trials using currently recommended amphotericinbased treatments [1, 2] , and the clinical course of illness in those who do survive is frequently complicated by prolonged or recurrent disease [3, 4] . Immune reconstitution inflammatory syndrome (IRIS) occurs in 15-20% of individuals who survive their initial illness and initiate antiretroviral therapy (ART), causing a further substantial burden of morbidity and mortality [3] [4] [5] [6] . Determining the underlying immune pathology of IRIS, with a view to developing effective prevention or treatment and enabling safe and rapid initiation of ART is, therefore, of considerable importance, and a core component of improving patient outcomes from this severe opportunistic infection. ideally, genotyping, with the ultimate aim of identifying pathways amenable to intervention to reduce the high rates of morbidity and mortality due to cryptococcal meningitis worldwide [31] . Pending these studies, efforts should be focused on reducing the incidence of C-IRIS through the use of rapidly fungicidal antifungal drug combinations [1, 2] and appropriately timed ART initiation [32, 33] based on evidence from randomized controlled trials, and ensuring clinicians recognize C-IRIS early and manage cases appropriately. Data from our recent trials suggest that with these steps in place the morbidity related to C-IRIS can be reduced substantially in patients initiating ART following cryptococcal meningitis [1, 4, 34] , and C-IRIS should no longer carry the devastating prognosis that has historically been associated with the condition.
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